ABL Diagnostics wins court approval to take over TEXCELL activities

ABL Diagnostics has been designated by the Évry commercial court to acquire TEXCELL’s assets and operations, a move that expands the company’s footprint in virology, biosafety and infectious disease work at Genopole in Évry-Courcouronnes. The deal includes 29 employees, ongoing commercial contracts and a planned industrial and technology investment program worth about 2.9 million euros.

Why it matters: - The TEXCELL takeover gives ABL Diagnostics a stronger position in life sciences and infectious diseases. - The deal preserves scientific capabilities in virology, biosafety and biological control at Genopole in Évry-Courcouronnes. - ABL Diagnostics also gains operating capacity that can support future research, quality control and molecular diagnostics work.

What happened: - The Tribunal de commerce d'Évry designated ABL Diagnostics to take over TEXCELL’s assets and activities. - The announcement was made July 22, 2026. - The acquisition covers strategic assets and operations, commercial contracts transferred in the deal, and continued activity at the Genopole site. - ABL Diagnostics will take on 29 TEXCELL employees, including 23 permanent staff and 6 alternates. - The company will also assume acquired employee rights valued at 91,829.24 euros, subject to adjustment.

The details: - TEXCELL has scientific roots linked to the Institut Pasteur ecosystem. - TEXCELL’s expertise includes viral safety, biosafety, genomic analysis, immune monitoring, cell culture, viral characterization and services for biotech and innovative therapies. - Publicly available information cited in the release shows TEXCELL France generated about 5.4 million euros in revenue in 2024, down from 6.2 million euros in 2023 and 7.5 million euros in 2022. - The overall economic value of the project is about 2.9 million euros. - The asset purchase price is 225,000 euros, including 165,000 euros for intangible assets and 60,000 euros for tangible assets. - ABL Diagnostics will buy inventories for a flat 30,000 euros excluding tax. - The company will reconstitute security deposits for about 100,000 euros. - The takeover includes credit-lease contracts tied to operational equipment and upcoming installments worth 531,792.74 euros, subject to adjustment. - The plan includes 930,000 euros in industrial and technology investment. - The plan also includes 1 million euros in additional working capital to support the acquired business. - The operation will be financed from ABL Diagnostics’ available cash resources. - The terms of the winning bid are in documents filed with the Évry commercial court.

Between the lines: - The takeover fits ABL Diagnostics’ broader strategy to deepen its work in molecular diagnostics, virology and infectious diseases. - The company frames the move as complementary to its existing UltraGene, DeepChek® and Nadis® platforms. - The purchase also strengthens ABL Diagnostics’ ties to the Institut Pasteur scientific ecosystem, following a recent HPV RNA-Seq genotyping project with the Institut Pasteur de Paris. - Management is signaling a build-and-integrate strategy, not just a pure asset purchase. - The planned recruitment of about five additional employees suggests ABL Diagnostics expects to grow the Genopole site rather than maintain it at current size. - The company also said the acquired virus banks, cell lines, virology expertise and biosafety infrastructure could support future tools for biomedical research, biological quality control and molecular diagnostics. - Dr. Chalom Sayada said the transaction brings recognized scientific skills, qualified teams, an established international brand and complementary biological assets.

What's next: - ABL Diagnostics will complete the required legal and administrative formalities. - The company will later disclose how it will integrate the acquired activities into its strategic roadmap and 2026 goals. - ABL Diagnostics plans to invest in automation, infrastructure upgrades, team growth and scientific development after closing. - The company expects the combined platform to serve laboratories, research centers, biotechs and healthcare manufacturers internationally.

The bottom line: - ABL Diagnostics is turning a court-approved acquisition into a broader push into virology and biosafety, while locking in talent, assets and a strategic site at Genopole.